# Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

> **NCT02145182** · PHASE2,PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 288 (actual)

## Conditions studied

- Delayed Graft Function

## Interventions

- **DRUG:** Eculizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02145182
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-21
- **Primary completion:** 2016-11-22
- **Final completion:** 2016-11-22
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2018-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145182, "Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02145182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*